INVESTMENT

BI is presently securing $2 million in seed capital for its commercialization program. This financing round is expected to close on 1.11.2017, after which the BI action plan will be initiated. Interested investors should contact Dr. Sigalit Carmel, Founder and CEO at: sigalit@bioimmunate.com; mobile 972-54-720-2228.

This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, visit About Cookies page.